| Literature DB >> 22860078 |
Rachel M Schowalter1, William C Reinhold, Christopher B Buck.
Abstract
Merkel Cell Polyomavirus (MCV or MCPyV) was recently discovered in an aggressive form of skin cancer known as Merkel cell carcinoma (MCC). Integration of MCV DNA into the host genome likely contributes to the development of MCC in humans. MCV infection is common and many healthy people shed MCV virions from the surface of their skin. MCV DNA has also been detected in samples from a variety of other tissues. Although MCC tumors serve as a record that MCV can infect the Merkel cell lineage, the true tissue tropism and natural reservoirs of MCV infection in the host are not known. In an effort to gain insight into the tissue tropism of MCV, and to possibly identify cellular factors responsible for mediating infectious entry of the virus, the infection potential of human cells derived from a variety of tissues was evaluated. MCV gene transfer vectors (pseudoviruses) carrying reporter plasmid DNA encoding GFP or luciferase genes were used to transduce keratinocytes and melanocytes, as well as lines derived from MCC tumors and the NCI-60 panel of human tumor cell lines. MCV transduction was compared to transduction with pseudoviruses based on the better-studied human BK polyomavirus (BKV). The efficiency of MCV and BKV transduction of various cell types occasionally overlapped, but often differed greatly, and no clear tissue type preference emerged. Application of native MCV virions to a subset of highly transducible cell types suggested that the lines do not support robust replication of MCV, consistent with recent proposals that the MCV late phase may be governed by cellular differentiation in vivo. The availability of carefully curated gene expression data for the NCI-60 panel should make the MCV and BKV transduction data for these lines a useful reference for future studies aimed at elucidation of the infectious entry pathways of these viruses.Entities:
Mesh:
Year: 2012 PMID: 22860078 PMCID: PMC3409148 DOI: 10.1371/journal.pone.0042181
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Relative transducibility of NCI-60 Cell Lines.
| Viral Titer | RLUs (% of A549) | |||||
| Cell Line Name | Inoculation Density | Cancer of Origin | MCV-GFP | BKV-GFP | MCV-GLuc | BKV-GLuc |
| CCRF-CEM | 40000 | Leukemia | 18540 | 12593 | 0.31 | ND |
| HL-60(TB) | 40000 | Leukemia | 53698 | 52338 | 0.00 | ND |
| K-562 | 5000 | Leukemia | 32175 | 82938 | 1.54 | ND |
| MOLT-4 | 30000 | Leukemia | 0 | 0 | 0.06 | ND |
| RPMI-8226 | 20000 | Leukemia | 61645 | 132552 | 4.56 | ND |
| SR | 20000 | Leukemia | 72965 | 653293 | 1.32 | ND |
| A549/ATCC | 7500 | Non-Small Cell Lung Cancer | 4036276 | 4694740 | 100.00 | 100.00 |
| EKVX | 20000 | Non-Small Cell Lung Cancer | 551394 | 1850527 | ND | ND |
| EKVX | 10000 | Non-Small Cell Lung Cancer | 343382 | 4425743 | 52.84 | 285.05 |
| HOP-62 | 10000 | Non-Small Cell Lung Cancer | 70724 | 57185 | 2.80 | 1.01 |
| HOP-92 | 20000 | Non-Small Cell Lung Cancer | 1545942 | 367962 | 12.81 | ND |
| NCI-H226 | 20000 | Non-Small Cell Lung Cancer | 54044 | 21543344 | 2.46 | ND |
| NCI-H23 | 20000 | Non-Small Cell Lung Cancer | 481240 | 564377 | 42.41 | ND |
| NCI-H322M | 20000 | Non-Small Cell Lung Cancer | 297805 | 151958 | 10.17 | ND |
| NCI-H460 | 7500 | Non-Small Cell Lung Cancer | 30022 | 224570 | 3.51 | ND |
| NCI-H522 | 20000 | Non-Small Cell Lung Cancer | 121885 | 1025356 | 3.27 | 27.13 |
| COLO 205 | 15000 | Colon Cancer | 7591 | 9938 | 0.25 | ND |
| HCC-2998 | 15000 | Colon Cancer | 33965 | 197907 | 0.27 | 2.10 |
| HCT-116 | 5000 | Colon Cancer | 92748 | 4969471 | 6.51 | 190.19 |
| HCT-15 | 10000 | Colon Cancer | 64842 | 0 | 0.72 | 0.85 |
| HT29 | 5000 | Colon Cancer | 28156 | 1363256 | 1.43 | ND |
| KM12 | 15000 | Colon Cancer | 37477 | 84911 | 1.15 | 6.58 |
| SW-620 | 10000 | Colon Cancer | 36340 | 4102580 | 0.72 | ND |
| SF-268 | 15000 | CNS Cancer | 304884 | 1492174 | 32.82 | 53.03 |
| SF-295 | 10000 | CNS Cancer | 46983 | 2970000 | 1.93 | ND |
| SF-539 | 15000 | CNS Cancer | 3563441 | 4433878 | 18.20 | 33.04 |
| SNB-19 | 15000 | CNS Cancer | 391984 | 1270160 | 3.80 | 36.50 |
| SNB-75 | 20000 | CNS Cancer | 438260 | 4097809 | 2.83 | ND |
| U251 | 7500 | CNS Cancer | 48585 | 977771 | 0.36 | ND |
| LOX IMVI | 7500 | Melanoma | 54527 | 491927 | 0.56 | ND |
| MALME-3M | 20000 | Melanoma | 6350615 | 123229 | 285.04 | 1.41 |
| M14 | 15000 | Melanoma | 252053 | 276480 | 31.60 | ND |
| SK-MEL-2 | 20000 | Melanoma | 4325015 | 1454820 | 659.79 | ND |
| SK-MEL-28 | 10000 | Melanoma | 2064602 | 0 | 34.50 | 6.27 |
| SK-MEL-5 | 10000 | Melanoma | 4690038 | 37667 | 558.26 | ND |
| UACC-257 | 20000 | Melanoma | 889504 | 160761 | 383.18 | ND |
| UACC-62 | 10000 | Melanoma | 3174044 | 523162 | 328.73 | 47.71 |
| MDA-MB-435 | 15000 | Melanoma | 3807258 | 913337 | 228.80 | ND |
| IGR-OV1 | 10000 | Ovarian Cancer | 188042 | 1156548 | 0.77 | 7.87 |
| OVCAR-3 | 10000 | Ovarian Cancer | 3806616 | 4700732 | 133.37 | ND |
| OVCAR-4 | 10000 | Ovarian Cancer | 56135 | 18150671 | 52.23 | 527.06 |
| OVCAR-5 | 20000 | Ovarian Cancer | 49767 | 16918 | 0.03 | 1.20 |
| OVCAR-8 | 10000 | Ovarian Cancer | 2199023 | 16645456 | 33.76 | 361.46 |
| SK-OV-3 | 20000 | Ovarian Cancer | 35549 | 1526071 | 0.45 | 6.66 |
| NCI/ADR-RES** | 15000 | Ovarian Cancer | 17084329 | 25828518 | 571.62 | 448.29 |
| 786–0 | 10000 | Renal Cancer | 63979 | 76850 | 0.35 | ND |
| A498 | 25000 | Renal Cancer | 203031 | 2436377 | ND | ND |
| ACHN | 10000 | Renal Cancer | 20727 | 112273 | 0.47 | 0.61 |
| CAKI-1 | 10000 | Renal Cancer | 1826882 | 960036 | 41.42 | 7.54 |
| RXF 393 | 15000 | Renal Cancer | 63262 | 10027078 | 0.09 | ND |
| SN12C | 15000 | Renal Cancer | 608850 | 1487265 | 16.00 | 37.41 |
| TK-10 | 15000 | Renal Cancer | 464909 | 2059778 | 1.13 | 14.02 |
| UO-31 | 15000 | Renal Cancer | 156469 | 130502 | 2.05 | 1.37 |
| PC-3 | 7500 | Prostate Cancer | 175126 | 106887 | 10.74 | ND |
| DU-145 | 10000 | Prostate Cancer | 2042776 | 270406 | 46.76 | ND |
| MCF7 | 10000 | Breast Cancer | 564819 | 2684677 | 40.18 | 69.90 |
| MDA-MB-231/ATCC | 20000 | Breast Cancer | 923625 | 942535 | 28.71 | 18.55 |
| HS 578T | 20000 | Breast Cancer | 126749 | 449933 | ND | ND |
| HS 578T | 5000 | Breast Cancer | 1217837 | 5645014 | 19.86 | ND |
| MDA-MB-468 | 20000 | Breast Cancer | 4386206 | 706258 | 236.97 | 19.21 |
| BT-549 | 20000 | Breast Cancer | 29341 | 131896 | 0.30 | ND |
| T-47D | 20000 | Breast Cancer | 269198 | 46503560 | 4.43 | ND |
The cells listed in column one were plated in 96-well plates at the density shown the day prior to addition of MCV or BKV pseudoviruses. The viral titer of GFP-reporter pseudoviruses was determined by flow cytometry. GLuc-reporter transduction was measured by luminometry following injection of substrate. Relative light units (RLUs) are displayed as a percentage of A549 cell transduction RLUs. ND = not determined.
Once considered a breast cancer cell line, studies have shown that MDA-MB-435 cells were derived from the M14 melanoma cell line, and the gene expression profile of these cells resembles that of other melanoma cells. **Once considered a breast cancer cell line, studies have shown that NCI/ADR-RES cells were derived from the OVCAR-8 ovarian cancer cell line, and the gene expression profile of these cells resembles that of OVCAR-8.
Figure 1Transducivity of NCI-60 Cell Lines.
A graphical representation of the GFP-reporter pseudovirus titers listed in Table 1.
Figure 2Correlations between GFP titers and relative GLuc transduction.
The correlation between GFP-reporter pseudovirus titers and relative GLuc-reporter pseudovirus RLUs for each NCI-60 cell line examined with both types of pseudovirus is shown. R2 values were calculated with Prism software using the Pearson two-tailed correlation test. The poor correlation between MCV-GFP and BKV-GFP titers is also shown.
The top 100 genes that correlate with viral titers.
| MCV transduction correlated genes | BKV transduction correlated genes | ||||||||||
| Gene Name |
| Gene Name |
| Gene Name |
| Gene Name |
| ||||
|
| RUNDC3B | 0.845 |
| FMN2 | 0.514 |
| DNALI1 | 0.776 |
| GNMT | 0.664 |
|
| RPL17P4 | 0.814 |
| OR14K1 | 0.514 |
| OTOR | 0.766 |
| C6orf165 | 0.662 |
|
| ZCWPW2 | 0.788 |
| MSLN | 0.512 |
| CPAMD8 | 0.753 |
| NCRNA00257 | 0.66 |
|
| TCEAL2 | 0.745 |
| PPP1R14A | 0.51 |
| AGXT2 | 0.752 |
| PDZD2 | 0.658 |
|
| SLC13A5 | 0.744 |
| ATG9B | 0.51 |
| RSL24D1P9 | 0.75 |
| ELF5 | 0.657 |
|
| RGS7BP | 0.742 |
| GNAO1 | 0.507 |
| POU2F3 | 0.744 |
| C5orf58 | 0.656 |
|
| MAGEL2 | 0.733 |
| NEFHP1 | 0.504 |
| PIP | 0.742 |
| AMZ1 | 0.655 |
|
| PNMA3 | 0.732 |
| C2orf49 | 0.5 |
| PCP4L1 | 0.741 |
| INPP5J | 0.652 |
|
| AHSG | 0.725 |
| CTCFL | 0.497 |
| CDC20B | 0.738 |
| ABCC6 | 0.651 |
|
| ZNF157 | 0.698 |
| CPB1 | 0.497 |
| TDPX2 | 0.738 |
| CCDC42B | 0.641 |
|
| DNAJC5G | 0.687 |
| IL1RL2 | 0.492 |
| AASDHPPT | 0.738 |
| SEPP1 | 0.639 |
|
| CEACAMP5 | 0.674 |
| NEFH | 0.491 |
| PHACTR1 | 0.736 |
| MFSD7 | 0.638 |
|
| C11orf85 | 0.655 |
| FAM70A | 0.49 |
| CLDN8 | 0.734 |
| FKBP1AP1 | 0.638 |
|
| SNAP91 | 0.633 |
| RING1 | 0.483 |
| KLF8 | 0.734 |
| PIH1D2 | 0.637 |
|
| LYVE1 | 0.622 |
| CCNYL2 | 0.476 |
| SERPINA6 | 0.734 |
| ARHGAP40 | 0.631 |
|
| OR10A6 | 0.618 |
| PDE6B | 0.47 |
| ACER1 | 0.734 |
| ADHFE1 | 0.628 |
|
| IQSEC3 | 0.613 |
| TCAM1P | 0.468 |
| TRPV6 | 0.732 |
| TNKS1BP1 | 0.626 |
|
| KBTBD12 | 0.612 |
| RPS6P9 | 0.468 |
| BNIPL | 0.73 |
| SPINK13 | 0.626 |
|
| SEMA3D | 0.61 |
| GALC | 0.467 |
| PGR | 0.729 |
| C1orf88 | 0.624 |
|
| RASIP1 | 0.605 |
| SEMA3E | 0.464 |
| CYP4Z2P | 0.728 |
| C11orf52 | 0.624 |
|
| CCR10 | 0.598 |
| DCI | 0.464 |
| PDE6H | 0.724 |
| MPP7 | 0.622 |
|
| MEI1 | 0.597 |
| IGFBPL1 | 0.462 |
| ABCC11 | 0.723 |
| CRISP3 | 0.621 |
|
| RFPL4A | 0.594 |
| BEX5 | 0.462 |
| KRT8P16 | 0.723 |
| KCTD6 | 0.614 |
|
| ADCY5 | 0.59 |
| TNNT2 | 0.462 |
| ABCC12 | 0.723 |
| NCAM2 | 0.611 |
|
| C4orf44 | 0.588 |
| NAP1L3 | 0.459 |
| TRPV3 | 0.72 |
| PLEKHG4B | 0.611 |
|
| KCTD8 | 0.584 |
| FAM100A | 0.459 |
| XG | 0.719 |
| PCDHGA1 | 0.61 |
|
| OR6W1P | 0.579 |
| MAEA | 0.457 |
| CYP1A2 | 0.714 |
| C6orf154 | 0.61 |
|
| ABCB1 | 0.578 |
| TRBVAOR9–2 | 0.455 |
| C1orf64 | 0.714 |
| CALCOCO1 | 0.609 |
|
| NLRP10 | 0.574 |
| INPP4B | 0.454 |
| RTP1 | 0.714 |
| RPS17P2 | 0.606 |
|
| OR9A2 | 0.57 |
| CLIP3 | 0.454 |
| TRIL | 0.712 |
| C4orf19 | 0.6 |
|
| STAG3 | 0.57 |
| HCP5P14 | 0.45 |
| HPX | 0.712 |
| ZMYND10 | 0.599 |
|
| FLT4 | 0.558 |
| DPH3 | 0.45 |
| CYP2T2P | 0.709 |
| TTC6 | 0.597 |
|
| RAMP2 | 0.556 |
| PSG9 | 0.446 |
| EGOT | 0.707 |
| RMST | 0.596 |
|
| ABCB4 | 0.556 |
| OR5K2 | 0.444 |
| C1orf168 | 0.706 |
| RERG | 0.595 |
|
| ANKRD6 | 0.554 |
| LYRM2 | 0.444 |
| ABCC13 | 0.702 |
| PKD1L1 | 0.595 |
|
| ACTC1 | 0.553 |
| C9orf85 | 0.442 |
| PNPLA7 | 0.697 |
| FLT4 | 0.593 |
|
| HLA-L | 0.552 |
| LAMC3 | 0.441 |
| C9orf150 | 0.695 |
| HOXC4 | 0.593 |
|
| GNGT2 | 0.541 |
| PCLO | 0.44 |
| BACH1 | 0.693 |
| SPINK5 | 0.593 |
|
| NHLRC1 | 0.541 |
| LGI3 | 0.438 |
| POU6F2 | 0.691 |
| SYT8 | 0.592 |
|
| SMC1B | 0.541 |
| KRTAP4–7 | 0.437 |
| PRLR | 0.689 |
| TMPRSS13 | 0.591 |
|
| C14orf167 | 0.539 |
| HDAC5 | 0.435 |
| MAP6D1 | 0.687 |
| TRIM17 | 0.587 |
|
| RPS9P2 | 0.536 |
| MMP27 | 0.432 |
| CYP4X1 | 0.686 |
| TNNI2 | 0.581 |
|
| RPL26P13 | 0.535 |
| RILPL1 | 0.431 |
| CYP4Z1 | 0.685 |
| PXMP4 | 0.578 |
|
| NCRNA00107 | 0.534 |
| C17orf104 | 0.428 |
| BFSP2 | 0.685 |
| RANBP3L | 0.577 |
|
| SNORA11C | 0.533 |
| AEBP1 | 0.427 |
| PTGER3 | 0.679 |
| HOXC6 | 0.577 |
|
| RSPO4 | 0.531 |
| SYCP1 | 0.425 |
| ZNF552 | 0.678 |
| SPEF2 | 0.576 |
|
| RGS9 | 0.524 |
| ZFYVE26 | 0.424 |
| RPLP0P2 | 0.677 |
| RLN2 | 0.576 |
|
| TMEM174 | 0.523 |
| GNAL | 0.423 |
| C10orf71 | 0.676 |
| IVL | 0.574 |
|
| ABI3 | 0.521 |
| LAMA1 | 0.421 |
| DLL1 | 0.665 |
| GRIK4 | 0.573 |
|
| LDHC | 0.518 |
| C17orf72 | 0.421 |
| CLIC3 | 0.665 |
| C9orf24 | 0.573 |
Transducibility of other potentially relevant cell lines and primary cells.
| Viral Titer | RLUs (% of A549) | |||||
| Cell Line Name | Inoculation Density | Cell Origin | MCV-GFP | BKV-GFP | MCV-GLuc | BKV-GLuc |
| UISO | 7500 | Merkel Cell Carcinoma (MCV-) | 165000 | 1680000 | 0.73 | 2.00 |
| MaTi | ∼10000 | MCC Lymph Node Metastisis (MCV-) | 0 | 0 | 0.03 | 0.05 |
| WaGa | ∼10000 | MCC Patient Ascites (MCV+) | 240000 | 0 | 0.04 | 0.02 |
| MKL-1 | ∼10000 | MCC Nodal Metastasis (MCV+) | 0 | 0 | 0.07 | 0.03 |
| HeLa | 5000 | Cervical Adenocarcinoma | 160000 | 2160000 | 0.05 | ND |
| HaCaT | 7500 | Transformed Keratinocyte | 0 | 0 | 0.00 | 0.00 |
| HEKa | 3500 | Primary Human Adult Keratinocyte | 1113000 | 14952000 | ND | ND |
| HEMn | 10000 | Primary Human Epidermal Melanocyte | 90000 | 360000 | 0.00 | 0.08 |
| PFSK-1 | 7500 | Primitive neuroectodermal tumor | 435000 | 577500 | ND | ND |
The cells listed in column one were plated in 96-well plates at the density shown the day prior to addition of MCV or BKV pseudoviruses. The viral titer of GFP-reporter pseudoviruses was determined by flow cytometry. GLuc-reporter transduction was measured by luminometry following injection of substrate. Relative light units (RLUs) are displayed as a percentage of A549 cell transduction RLUs. ND = not determined.
Figure 3Replication of Native MCV and BKV in infected NCI-60 cells.
NCI-60 cell lines with high MCV titers and 293–4 T cells were inoculated with native MCV or BKV in duplicate. The following day, one sample from each cell type was collected and frozen while the other was re-plated. On the fourth day, the second sample was collected. Low molecular weight DNA was purified and the number of MCV or BKV genomic copies was determined by quantitative PCR. One representative experiment of four is shown.